Suppr超能文献

微管蛋白——抗癌治疗的靶点。

Tubulins - the target for anticancer therapy.

作者信息

Vindya N G, Sharma Nishant, Yadav Mukesh, Ethiraj K R

机构信息

School of Advanced Sciences, VIT University, Vellore, 632014, India.

出版信息

Curr Top Med Chem. 2015;15(1):73-82. doi: 10.2174/1568026615666150112115805.

Abstract

Tubulin has picked up great focus as a major target in drug discovery and consequently, tubulin inhibitors have pulling in a considerable attention as anticancer agents. Numerable naturally occurring agents have focused on tubulin system act as an imperative target of cancer chemotherapy. Substantial number of tubulin inhibitors has been discovered so far and these agents are classified as indicated by their interaction. They are colchicine site binder, vinca- alkaloid related drugs and those interacting with the Taxol binding site and functioning as stabilising agents. We review the recent advances in the advancement of tubulin interfering agents and will render the current trend in the improvement of tubulin inhibitors as anticancer agents.

摘要

微管蛋白作为药物研发的主要靶点已备受关注,因此,微管蛋白抑制剂作为抗癌药物也引起了相当大的关注。许多天然存在的药物都聚焦于微管蛋白系统,将其作为癌症化疗的重要靶点。到目前为止,已经发现了大量的微管蛋白抑制剂,这些药物根据其相互作用进行分类。它们是秋水仙碱位点结合剂、长春花生物碱相关药物以及那些与紫杉醇结合位点相互作用并起稳定剂作用的药物。我们综述了微管蛋白干扰剂的最新进展,并将呈现微管蛋白抑制剂作为抗癌药物改进的当前趋势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验